{"organizations": [], "uuid": "0fd198a2e6bb7e9626028ac410f699f17ca2fd43", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets", "section_title": "Markets &amp; Finance News | Reuters.com", "url": "https://www.reuters.com/article/brief-moleculin-expands-leukemia-develop/brief-moleculin-expands-leukemia-development-portfolio-with-immuno-stimulating-stat3-inhibitor-idUSFWN1P50I4", "country": "US", "domain_rank": 408, "title": "BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-10T21:43:00.000+02:00", "replies_count": 0, "uuid": "0fd198a2e6bb7e9626028ac410f699f17ca2fd43"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-moleculin-expands-leukemia-develop/brief-moleculin-expands-leukemia-development-portfolio-with-immuno-stimulating-stat3-inhibitor-idUSFWN1P50I4", "ord_in_thread": 0, "title": "BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "moleculin biotech inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 10, 2018 / 1:43 PM / Updated 25 minutes ago BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor Reuters Staff \nJan 10 (Reuters) - Moleculin Biotech Inc: \n* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR \n* MOLECULIN BIOTECH INC - EXPANDED COMPANYâ€˜S DEVELOPMENT PIPELINE FOR TREATMENT OF ACUTE MYELOID LEUKEMIA WITH AN IMMUNO-STIMULATING STAT3 INHIBITOR Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T21:43:00.000+02:00", "crawled": "2018-01-10T16:03:01.039+02:00", "highlightTitle": ""}